Can 3D imaging make prostate radiation more precise and worth the cost?

NCT ID NCT00433706

NEW Completed Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This trial tests whether using 3D on-board imaging before each radiation session improves accuracy and outcomes for men with prostate cancer compared to standard imaging. The study tracks disease-free survival, side effects, and costs over 2 to 5 years. It aims to find the best imaging strategy that balances effectiveness with expense.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 3D on-board imaging (cone-beam imaging) during radiation therapy
What this could lead to: If effective, this could establish 3D imaging as a standard, cost-effective way to improve radiation accuracy and reduce side effects in prostate cancer treatment.
What could go wrong: The trial is early in assessing long-term outcomes, and the cost-effectiveness may not favor routine use. There is also a risk that more frequent imaging could increase costs without significantly improving survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Institut Gustave Roussy

Villejuif, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.